An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients

F. Crea, L. Fornaro, E. Paolicchi, G. Masi, P. Frumento, F. Loupakis, L. Salvatore, C. Cremolini, M. Schirripa, F. Graziano, M. Ronzoni, V. Ricci, W. L. Farrar, A. Falcone, R. Danesi

Research output: Contribution to journalArticle

Abstract

Background: Despite therapeutic innovations, metastatic colorectal cancer (mCRC) is still characterized by poor prognosis and few molecular markers predict the risk of progression. Polycomb group genes (PcGs) are epigenetic modifiers involved in tumor suppressor gene silencing. PcG member EZH2 mediates gene silencing through histone-H3 lysine-27 methylation. In colorectal cancer (CRC), EZH2 overexpression predicts shorter survival. Recently, four EZH2 single-nucleotide polymorphisms (SNPs) have been described. The present study was aimed at evaluating the correlation between EZH2 SNPs and outcome parameters in mCRC patients. Patients and methods: DNA was extracted from blood samples of 110 mCRC patients treated with first-line 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) and bevacizumab. Genotyping was carried out by real-time PCR. Genotype was used to predict objective response, progression-free survival (PFS) and overall survival (OS). EZH2 messenger RNA levels were evaluated on lymphocytes of a parallel cohort of 50 CRC patients. Results: One allelic variant (rs3757441 C/C versus C/T or T/T) was significantly associated with shorter PFS and OS (P <0.01 and P <0.05, respectively). At multivariate analysis, the same variant resulted an independent predictor of PFS and OS (P <0.05). The C/C variant was associated with significantly higher EZH2 expression (P <0.05). Conclusion: An EZH2 SNP may be useful to predict clinical outcome in mCRC patients.

Original languageEnglish
Pages (from-to)1207-1213
Number of pages7
JournalAnnals of Oncology
Volume23
Issue number5
DOIs
Publication statusPublished - May 2012

Keywords

  • Cancer stem cell
  • Colorectal cancer
  • EZH2
  • FOLFIRI
  • Polycomb
  • Polymorphism

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Crea, F., Fornaro, L., Paolicchi, E., Masi, G., Frumento, P., Loupakis, F., Salvatore, L., Cremolini, C., Schirripa, M., Graziano, F., Ronzoni, M., Ricci, V., Farrar, W. L., Falcone, A., & Danesi, R. (2012). An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology, 23(5), 1207-1213. https://doi.org/10.1093/annonc/mdr387